title: Epigenetic treatment of neurological disease.
abstract: Neurological disease, and in particular neurodegenerative diseases, cause significant burdens on both patient and healthcare costs. Despite extensive research, treatment options for patients with these conditions remain limited, and generally, only provide modest symptomatic relief. Aberrant epigenetic post-translational modifications of proteins are emerging as important elements in the pathogenesis of neurological disease. Using Alzheimer's disease and Huntington's disease as examples in the following article, some of latest data linking both the histone code and the various proteins that regulate this code to the pathogenesis of neurological disease are discussed. The current evidence suggesting that pharmacologically targeting one such family, the histone deacetylases, may be of potential benefit in the treatment of such diseases is also discussed. Finally, some of the potential mechanisms to specifically target these proteins within the neurological setting are discussed.
authors: Translational Cancer Research Group, Department of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital, James's Street, Dublin 8, Ireland. sgray@stjames.ie
authors: Steven G
authors: SG
authors: Gray
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D002082:Butylamines / Q000494:pharmacology; D002454:Cell Differentiation / Q000502:physiology; D059865:Endoplasmic Reticulum Stress / Q000187:drug effects; D044127:Epigenesis, Genetic / Q000235:genetics / Q000502:physiology*; D042421:Histone Code / Q000235:genetics / Q000502:physiology*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D006877:Hydroxamic Acids / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism / Q000502:physiology; D010654:Phenylbutyrates / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000235:genetics / Q000502:physiology*; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology; D014635:Valproic Acid / Q000494:pharmacology; D000077337:Vorinostat
chemical_list: C121358:4-phenylbutylamine; D002082:Butylamines; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D010654:Phenylbutyrates; D013267:Stilbenes; D000077337:Vorinostat; D014635:Valproic Acid; D006655:Histone Deacetylases; D000077185:Resveratrol